Latest "Galectin Therapeutics" News Stories

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease.

Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration ...

Galectin-3 test provides Doctors in Europe with new tool for assessing the prognosis of chronic heart failure patient

CE Marking for the ARCHITECT Galectin-3 assay...

Galectin Therapeutics, Dr. Geert-Jan Boons’ laboratory partner for drug discovery program

US-based therapeutics developer Galectin Therapeutics (GALT) has announced that it has teamed up with Dr. Geert-Jan Boons’ laboratory at Georgia University for the establishment of a collaborative drug discovery program for new Anti-Galectin drugs...

Abbott: Galectin-3 Assay Sees Approval And Builds Takeover Case For La Jolla Pharmaceuticals

By Brian L. Wilson: Abbott Bringing More Interest to Galectin-3 We saw fresh news regarding Galectin-3 last week from Abbott Labs (ABT), which continued its excellence in the diagnostic products market with the CE marking of the Architect Galectin-3 assay in Europe (link). Note that the CE Marking is similar to an FDA approval, and clears the product for market launch.This is exciting, as Galec...

Galectin wins US patent for chronic liver disease therapy

The USPTO has granted Galectin Therapeutics a notice of issuance for a patent covering methods of derivation and use for carbohydrate-based galectin inhibitor compound for use in patients with chronic liver disease associated with the development of...

Galectin to relocate headquarters to Atlanta

Galectin Therapeutics, a developer of therapeutics that target galectin proteins to treat fibrosis and cancer, will be relocating its corporate offices to Atlanta, Ga., effective October 1, 2012, while maintaining a laboratory-based effort in the Bos...

BG Medicine seeks FDA clearence for ARCHITECT Galectin-3 assay

Cardiovascular diagnostics developer BG Medicine has filed a 510(k) Premarket Notification with the US Food and Drug Administration (FDA) for regulatory clearance for the ARCHITECT Galectin-3 assay.

Atherotech offers galectin-3 testing services

BG Medicine has announced the availability of galectin-3 testing services through Atherotech Diagnostics Lab.

BG Medicine files 510(k) application for galectin-3 test

BG Medicine has submitted to the FDA an application seeking 510(k) clearance for the ARCHITECT Galectin-3 test.  -More- 

Abbott's ARCHITECT Galectin-3 assay earns CE mark

Abbott today announced CE Marking (Conformite Europeenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure.

Galectin Therapeutics: Turning Atlanta into America's Next Silicon Valley

NORCROSS, Ga., April 4, 2013 /PRNewswire/ -- Gilbert Amelio, former CEO of Apple, and Rod Martin, former counsel to PayPal, both on the Board of Directors of Galectin Therapeutics (NASDAQ: GALT) authored an opinion piece in today's Atlanta Journal Constitution discussing the future of Atlanta as the emerging Silicon Valley for changing the world by curing the big diseases, and why they moved Galec...

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on J...

Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press

(PRWEB) February 07, 2013 Research Reports in Clinical Cardiology has published " Galectin-3: clinical utility and prognostic value in patients with heart failure ". This review summarizes the key findings of fourteen clinical trials...

Galectin Therapeutics to Present at the RedChip Small-Cap Equities Virtual Conference

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it will present at the RedChip Small-Cap Equities Virtual Conference. The Company’s presentation will be webcast live at http://www.redchip.com on August 30, 2012, beginning at 10:30 AM...

Protein Discovered That Promotes Cancers, Heart Disease; Substance Created To Block Its Effects

Strong scientific evidence suggests that high levels of a blood protein called galectin-3 may increase the risk of heart attacks, cancer and other diseases, and help forecast the outcome of those diseases, a scientist reported at the 244th National M...

Atherotech to offer BG Medicine galectin-3 testing services

Atherotech Diagnostics Lab, a CLIA-certified clinical reference laboratory, has entered into an agreement to offer BG Medicine's galectin-3 testing services to laboratory customers and physicians.

EU grants CE mark to BG Medicine automated Galectin-3 blood test

BG Medicine has obtained CE mark certification for its automated Galectin-3 blood test, designed for the management of chronic heart failure.

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of P...

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology...

BG Medicine files Galectin-3 assay premarket notification with FDA

BG Medicine has registered a 510(k) premarket notification with the US Food and Drug Administration (FDA) for approval of its Architect Galectin-3 assay.

Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders

ATLANTA, May 15, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:30 A.M. Eastern Time on Thursday, May 23, 2013, to provide an update following the Company's Annual Meeting of Shareholders. Additionally, Peter Traber, MD, President, CEO and CMO of Galectin Therapeutics, will update the investment community on the Company's pipeline of galectin inhibi...

Galectin Therapeutics provides details on first-in-man Phase 1 clinical trial of GR-MD-02

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatm...

Galectin Therapeutics Executive Chairman, James Czirr to Appear on “The RedChip Money Report” on FOX Business News

James Czirr, Executive Chairman of Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, will be a guest on “The RedChip Money Report”™ television program featuring emerging growth companies on FOX Business News, Saturday, February 9, 2013 at 2:30 p.m. Eastern....

Kindstar Diagnostics to Offer BG Medicine’s Cardiac Test

BG Medicine, a US maker of cardiac diagnostic tests, has entered into an agreement with Kindstar Diagnostics Co., the largest diagnostic testing lab in China. Under the terms of the pact, Kindstar will be able to offer BGM’s galectin-3 testi...